Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03264066 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT03264066 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 87 participants.
The verdict
NCT03264066, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab in participants with advanced solid tumors including the following cohorts: squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and renal cell carcinoma (RCC).
Interventions
- DRUG Atezolizumab
- DRUG Cobimetinib
- DRUG Atezolizumab Cohort 7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2017-11-23 |
| Est. Completion | 2020-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03264066
The ClinicalTrials.gov registry entry for NCT03264066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03264066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03264066 about?
NCT03264066 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors". This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab in participants with advanced solid tumors including the following cohorts: squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and renal cell carcinoma (RCC).
What is the current status of trial NCT03264066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2017-11-23. Estimated completion is 2020-06-25.
What interventions are being tested in trial NCT03264066?
The interventions under investigation include: Atezolizumab (DRUG), Cobimetinib (DRUG), Atezolizumab Cohort 7 (DRUG).
Who is sponsoring clinical trial NCT03264066?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.